Rifaximin (Xifaxan) for IBS-D: Dosing, Duration, and Management
For diarrhea-predominant IBS, rifaximin 550 mg three times daily for 14 days is the FDA-approved regimen, with retreatment permitted up to 2 additional times if symptoms recur. 1, 2
Dosing and Administration
Standard FDA-approved regimen:
- Dose: 550 mg orally three times daily
- Duration: 14 days (2 weeks)
- Food: Can be taken with or without food 2
Retreatment protocol:
- Patients who initially respond but develop recurrent symptoms can be retreated up to 2 additional times with the same 14-day regimen 1
- The AGA conditionally recommends retreatment in responders who relapse (moderate certainty evidence) 1
- In the retreatment trial, rifaximin prevented recurrence (RR 0.93; 95% CI 0.88-0.99) with moderate certainty evidence 1
Efficacy Profile
What rifaximin treats best:
- Bloating: Most consistent benefit (RR 0.86; 95% CI 0.70-0.93) 1
- Stool consistency: Significant improvement in loose/watery stools 1, 3
- Global IBS symptoms: Modest but significant relief (40.7% vs 31.7% placebo; NNT=10.2) 3, 4
- Abdominal pain: Limited effect compared to other symptoms 5
Critical limitation: Rifaximin's effect on abdominal pain is notably weaker than its effect on diarrhea and bloating 5. If abdominal pain is the predominant symptom, consider alternative or adjunctive therapies.
Contraindications and Safety
Absolute contraindications:
- Hypersensitivity to rifaximin or any rifamycin antimicrobial agents 2
- Diarrhea complicated by fever or blood in stool 2
- Known or suspected Campylobacter jejuni, Shigella spp., or Salmonella spp. infection 2
Important warnings:
- Not suitable for systemic bacterial infections due to minimal absorption 2
- Discontinue if diarrhea worsens or persists >24-48 hours 2
- Risk of C. difficile-associated diarrhea (though rare) 2
- Exercise caution in severe hepatic impairment (Child-Pugh C) due to 20-fold increase in systemic exposure 2
Safety profile:
- Adverse events similar to placebo in clinical trials 1, 3
- Most common: headache, upper respiratory infection, nausea (≤10%) 4
- No evidence of bacterial resistance development in clinical trials 6
- Drug-related adverse events: RR 0.70 (95% CI 0.25-2.01) 1
Alternative Therapies When Rifaximin is Unsuitable
First-line alternatives (if rifaximin contraindicated or unavailable):
For predominant diarrhea:
- Loperamide: Strong recommendation for diarrhea control, though limited effect on pain/bloating 1, 5
- Titrate dose carefully to avoid constipation
- Very low quality evidence but widely used
For predominant abdominal pain:
- Antispasmodics: Weak recommendation for global symptoms and pain 5
- Side effects: dry mouth, visual disturbance, dizziness
- Various agents available (hyoscine, dicyclomine, peppermint oil)
Second-line alternatives:
5-HT3 receptor antagonists (likely most efficacious for IBS-D):
- Ondansetron: 4 mg once daily titrated to maximum 8 mg three times daily 5
- Weak recommendation, moderate-to-high quality evidence
- Most common side effect: constipation
- More widely available than alosetron/ramosetron
- Alosetron: 0.5 mg twice daily (restricted to women with severe IBS-D under risk management program) 1
- Start 0.5 mg twice daily; may increase to 1 mg twice daily after 4 weeks if needed
- Contraindicated if constipation develops
Eluxadoline:
- Dose: 100 mg twice daily (75 mg if hepatic impairment or OATP1B1 inhibitor use) 1
- Conditional recommendation, moderate certainty evidence 1
- Better for diarrhea/urgency than abdominal pain 1
- Absolute contraindications: No gallbladder, >3 alcoholic drinks/day, sphincter of Oddi dysfunction, pancreatitis history, bile duct obstruction, severe liver impairment 1
- Risk of pancreatitis (3 per 1000) and sphincter of Oddi dysfunction (5 per 1000) 1
Neuromodulators (for pain-predominant IBS-D):
- Tricyclic antidepressants: Strong recommendation, moderate quality evidence 5
- Start amitriptyline 10 mg once daily, titrate to 30-50 mg once daily
- Most effective for abdominal pain
- Requires careful patient counseling about rationale
- SSRIs: Weak recommendation, low quality evidence 5
- Consider if TCAs not tolerated
Clinical Decision Algorithm
Step 1: Identify predominant symptom
- Bloating/diarrhea predominant → Rifaximin first-line (if available and no contraindications)
- Pain predominant → Consider TCAs or antispasmodics first
- Mixed symptoms → Rifaximin or combination therapy
Step 2: If rifaximin chosen
- Prescribe 550 mg TID × 14 days
- Assess response at 2-4 weeks post-treatment
- If response then relapse → Retreatment permitted (up to 2 additional courses)
Step 3: If rifaximin contraindicated/unavailable
- Diarrhea control needed → Loperamide or ondansetron
- Pain control needed → TCAs (amitriptyline 10-50 mg) or antispasmodics
- Severe IBS-D in women → Consider alosetron (if available)
- No gallbladder/alcohol concerns → Avoid eluxadoline
Step 4: Consider combination therapy
- Rifaximin can be combined with neuromodulators for pain
- Most patients in HE trials used lactulose concomitantly (91%) 2
Common Pitfalls
- Don't use rifaximin for systemic infections - minimal absorption limits efficacy 2
- Don't continue beyond 48 hours if symptoms worsen - suggests non-E. coli pathogen 2
- Don't prescribe eluxadoline post-cholecystectomy - high pancreatitis risk 1
- Don't expect robust pain relief from rifaximin alone - consider adding TCA if pain predominant 5
- Don't use in severe hepatic impairment without caution - 20-fold increase in exposure 2